Study Summary
CAR T cells targeting CD19 have been approved for patients with relapsed or refractory ALL, failing two or more prior protocols. Several institutional-based studies with other CAR T cells targeting CD19 have demonstrated outstanding response rates in patients with refractory disease, and the ability of CAR T cells to clear CNS leukemia. Nevertheless, these cases are sparse and have never been reported collectively. Here, we aim to retrospectively assess toxicity and long term outcome of patients treated with CAR T cells for CNS relapse of ALL.
Want to learn more about this trial?
Request More InfoInterventions
No interventions listed.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Chaim Sheba Medical Center | Ramat Gan | Israel |